Please login to the form below

Not currently logged in
Email:
Password:

Arzerra

This page shows the latest Arzerra news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

The verdict is based on data from the RESONATE trials and a three-year follow-up study, one of which showed that in comparison with GlaxoSmithKline's Arzerra (ofatumumab), the BTK

Latest news

  • Novartis drug works in secondary progressive MS Novartis drug works in secondary progressive MS

    The drug is facing patent expiry in 2019, however, so with siponimod Novartis has a means of extending its franchise - which also includes recently-acquired CD20-targeteing drug Arzerra (ofatumumab) - once

  • Novartis buys rights to GSK's Arzerra in MS for $1bn Novartis buys rights to GSK's Arzerra in MS for $1bn

    Novartis buys rights to GSK's Arzerra in MS for $1bn. Comes after a recent ‘ asset swap’ between the firms worth $20bn . ... Novartis gained rights to Arzerra's (ofatumumab) cancer indications when it took over GSK's oncology portfolio earlier this

  • Imbruvica shines in combination trial Imbruvica shines in combination trial

    An earlier trial of the drug as a single-agent therapy in CLL indicated it was more effective than GlaxoSmithKline (GSK) and Genmab's Arzerra (ofatumumab).

  • England's Cancer Drugs Fund: Fixing a broken system England's Cancer Drugs Fund: Fixing a broken system

    GlaxoSmithKline has been the hardest hit in terms of drugs, given that three of its treatments: breast cancer medicine Tyverb (lapatinib), leukaemia drug Arzerra (ofatumumab) and non-adipocytic soft tissue sarcoma ... GlaxoSmithKline's Tyverb (lapatinib):

  • Pharma condemns Cancer Drugs Fund cuts Pharma condemns Cancer Drugs Fund cuts

    GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).

More from news
Approximately 9 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Option to acquire. 1250. GSK. Novartis. Arzerra [ofatumumab] anti CD20 monoclonal antibody in oncology indications.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics